后DAA时代抗HCV治疗的现状及存在问题  

Current situation and problems of anti-hepatitis C virus therapy in era of direct-acting antiviral agents

作　　者：张莹 颜学兵 

机构地区：[1]徐州医科大学附属医院感染性疾病科,江苏省徐州市221002

出　　处：《世界华人消化杂志》2017年第13期1135-1142,共8页World Chinese Journal of Digestology

基　　金：国家自然科学基金资助项目;No.81371867;江苏省医学科技专项-新型临床诊疗技术攻关基金资助项目;No.BL2014033;江苏省"科教兴卫"医学重点人才培养基金资助项目;No.RC2011117;江苏省"六大人才高峰"基金资助项目;No.2011-WS-068~~

摘　　要：近年来,由于直接抗病毒药物(direct-acting antiviral agents,DAAs)具有高效、使用方便、不良反应小、疗程短、临床治愈率高的优点,使其在临床的应用越来越广泛.许多著名的制药公司对其研究不断,其上市及更新的速度未减.随着DAAs的广泛应用及指南更新,抗丙型肝炎病毒(hepatitis C virus,HCV)的治疗已经步入全口服药物时期,即已经步入后DAA时代.但在使用DAAs抗HCV治疗过程中存在许多问题,使用时需谨慎.In recent years, direct-acting antiviral agents （DAAs） have been widely used in clinical practice because of their advantages of high efficacy, ease of use, good tolerability, short duration, and high rate of clinical cure. Since many well-known pharmaceutical companies have been continuously developing DAAs, the listing and update of these drugs are speeding up. With the widespread use of DAAs and the update of guidelines, anti-hepatitis C virus （HCV） treatment has entered an era of oral drug therapy, in other words, the DAA era. However, there are many problems in the use of DAAs for treatment of HCV, so we should be cautious in using them.

关 键 词：丙型肝炎病毒 慢性丙型肝炎 肝细胞癌 直接抗病毒药物 

分 类 号：R978.7[医药卫生—药品]